Analyst Tracker/Patrick Trucchio

Patrick Trucchio

Q: How accurate are Patrick Trucchio's stock ratings?

About 62% of Patrick's ratings were profitable over a one-year hold, with an average return of +5.8% per rating, measured by 13Foresight from historical prices.

Q: How is Patrick ranked?

Patrick Trucchio is ranked #478 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

H.C. Wainwright

Wall Street Analyst

★★★★☆

#478

on 13Foresight · ranked by our own returns

62%

Success Rate

+5.8%

Average Return

96 of 155 calls profitable · +3.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 62% of Patrick Trucchio's ratings turned a profit when each position was held for 1 year — averaging +5.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

415 Buy 3 Hold 0 Sell

Patrick's Stock Coverage 42 ratings · 2026-08-30

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
VYGR Voyager Therapeutics	Aug 27, 2026	BUY	Strong Buy +303.8% avg upside 23 analysts	$25.00 606.25% Upside	·	·
GB:FARN Faron Pharmaceuticals Oy	Aug 27, 2026	BUY	Strong Buy +2400.0% avg upside 1 analyst	$1000.00 2400.02% Upside	·	·
GOSS Gossamer Bio	Aug 26, 2026	BUY	Buy +3896.6% avg upside 17 analysts	$2.00 1075.76% Upside	·	·
NRXP NRX Pharmaceuticals	Aug 26, 2026	BUY	Strong Buy +947.9% avg upside 5 analysts	$45.00 1167.69% Upside	+4.6%	·
BEAM Beam Therapeutics	Aug 25, 2026	BUY	Strong Buy +77.4% avg upside 25 analysts	$80.00 172.76% Upside	-1.8%	·
ATAI Atai Beckley N.V.	Aug 21, 2026	HOLD	Buy +24.1% avg upside 17 analysts	$7.50 2.89% Upside	-0.4%	·
DRUG Bright Minds Biosciences	Aug 21, 2026	BUY	Strong Buy +84.0% avg upside 10 analysts	$145.00 99.10% Upside	-3.7%	·
MRKR Marker Therapeutics	Aug 20, 2026	BUY	Strong Buy +962.5% avg upside 9 analysts	$10.00 629.96% Upside	+22.9%	·
HELP Helus Pharma	Aug 20, 2026	BUY	Strong Buy +209.5% avg upside 13 analysts	$70.00 474.63% Upside	+6.2%	·
ONCY Oncolytics Biotech	Aug 20, 2026	BUY	Strong Buy +685.1% avg upside 12 analysts	$5.00 483.75% Upside	+6.2%	·
ASMB Assembly Biosciences	Aug 18, 2026	BUY	Strong Buy -0.6% avg upside 10 analysts	$50.00 46.84% Upside	+8.3%	·
ANRO Alto Neuroscience, Inc.	Aug 18, 2026	BUY	Strong Buy -9.0% avg upside 13 analysts	$55.00 56.56% Upside	+6.2%	·
IVVD Invivyd	Aug 18, 2026	BUY	Buy +738.9% avg upside 8 analysts	$10.00 936.87% Upside	+14.9%	·
ALT Altimmune	Aug 17, 2026	BUY	Strong Buy +763.1% avg upside 20 analysts	$20.00 543.15% Upside	+8.0%	·
SLN Silence Therapeutics	Aug 14, 2026	BUY	Strong Buy +160.1% avg upside 10 analysts	$75.00 458.89% Upside	-3.3%	·
AGMB AgomAb Therapeutics NV ADR	Aug 14, 2026	BUY	Strong Buy +162.5% avg upside 7 analysts	$35.00 165.66% Upside	+4.7%	·
PHVS Pharvaris	Aug 14, 2026	BUY	Strong Buy +31.0% avg upside 15 analysts	$60.00 69.90% Upside	+5.3%	·
DFTX Definium Therapeutics	Aug 13, 2026	BUY	Strong Buy +26.3% avg upside 22 analysts	$70.00 70.83% Upside	-0.3%	·
DTIL Precision BioSciences	Aug 12, 2026	BUY	Strong Buy +203.8% avg upside 12 analysts	$60.00 671.30% Upside	+13.2%	·
HRMY Harmony Biosciences Holdings	Aug 12, 2026	BUY	Strong Buy +25.7% avg upside 14 analysts	$55.00 40.21% Upside	+0.2%	·
IMCR Immunocore Holdings	Aug 12, 2026	BUY	Strong Buy +75.9% avg upside 22 analysts	$100.00 173.09% Upside	+5.8%	·
FTH Faeth Therapeutics	Aug 11, 2026	BUY	Strong Buy +35.3% avg upside 17 analysts	$60.00 77.36% Upside	+12.5%	·
GHRS GH Research	Aug 10, 2026	BUY	Strong Buy +41.9% avg upside 12 analysts	$65.00 132.62% Upside	-4.1%	·
ALGS Aligos Therapeutics	Aug 10, 2026	BUY	Strong Buy +565.6% avg upside 11 analysts	$50.00 623.56% Upside	-7.6%	·
VIR Vir Biotechnology	Aug 10, 2026	BUY	Strong Buy +137.5% avg upside 16 analysts	$20.00 84.72% Upside	+21.8%	·
ARWR Arrowhead Pharmaceuticals	Aug 07, 2026	BUY	Strong Buy -11.7% avg upside 27 analysts	$120.00 41.26% Upside	+1.1%	·
CMPS COMPASS Pathways	Aug 07, 2026	BUY	Strong Buy +61.7% avg upside 20 analysts	$65.00 373.32% Upside	+8.1%	·
ALNY Alnylam Pharma	Aug 04, 2026	BUY	Strong Buy +36.4% avg upside 51 analysts	$455.00 91.90% Upside	+8.3%	·
QURE uniQure	Jul 30, 2026	BUY	Strong Buy +21.3% avg upside 29 analysts	$80.00 64.27% Upside	+15.5%	·
SGMOQ Sangamo Therapeutics	Jun 09, 2026	HOLD	Buy +6884.4% avg upside 16 analysts	—	+0.0%	·
MIST Milestone Pharmaceuticals	Apr 02, 2025	BUY	Strong Buy +546.5% avg upside 8 analysts	$10.00 762.04% Upside	+71.9%	·
QTTB Q32 Bio	May 15, 2023	BUY	Buy +287.6% avg upside 25 analysts	$360.00 2295.19% Upside	+60.1%	·
TSE:PHRM PharmaTher Holdings Ltd	Feb 10, 2023	HOLD	Hold 1 analyst	—	+19.5%	·
BNTC Benitec Biopharma	Feb 10, 2023	HOLD	Strong Buy +100.4% avg upside 14 analysts	—	-37.9%	·
GB:AGY Allergy Therapeutics	Nov 02, 2022	BUY	Strong Buy +35803.6% avg upside 2 analysts	$46.03 707.48% Upside	-90.6%	·
DE:EVT Evotec	Mar 27, 2020	BUY	Buy +395.8% avg upside 8 analysts	$33.00 885.70% Upside	+46.1%	·
SUPN Supernus Pharmaceuticals	Nov 08, 2019	HOLD	Strong Buy +27.6% avg upside 9 analysts	$24.00 45.19% Downside	+8.6%	·
ENTA Enanta Pharmaceuticals	Sep 18, 2019	BUY	Buy +141.3% avg upside 17 analysts	$130.00 855.95% Upside	-34.7%	·
PRGO Perrigo Company	Nov 13, 2018	HOLD	Buy +370.9% avg upside 20 analysts	$72.00 397.22% Upside	-24.8%	·
INVA Innoviva	Apr 19, 2018	BUY	Buy +37.2% avg upside 12 analysts	$22.00 4.89% Upside	-19.3%	·
IRWD Ironwood Pharma	Apr 19, 2018	BUY	Buy +187.1% avg upside 23 analysts	$25.00 505.23% Upside	-23.6%	·
KMB Kimberly Clark	Dec 23, 2014	BUY	Buy +16.2% avg upside 30 analysts	$125.00 14.06% Upside	+11.2%	·

🔒 37 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Patrick Trucchio — Frequently Asked Questions

How accurate are Patrick Trucchio's stock ratings?

Based on the calls 13Foresight could measure, about 62% of Patrick's ratings were profitable over a one-year hold, with an average return of +5.8% per rating, or +3.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Patrick ranked on 13Foresight?

Patrick Trucchio is currently ranked #478 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Patrick cover?

Patrick most recently has ratings on VYGR, GB:FARN, GOSS, NRXP, BEAM, ATAI, DRUG, MRKR, HELP, ONCY, ASMB, ANRO and 30 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Patrick Trucchio

Rating Distribution

Welcome to 13Foresight!